Literature DB >> 23529066

Benznidazole prevents endothelial damage in an experimental model of Chagas disease.

Alfredo Molina-Berríos1, Carolina Campos-Estrada, Michel Lapier, Juan Duaso, Ulrike Kemmerling, Norbel Galanti, Mario Leiva, Jorge Ferreira, Rodrigo López-Muñoz, Juan Diego Maya.   

Abstract

OBJECTIVES: To evaluate the effect of benznidazole on endothelial activation in a murine model of Chagas disease.
METHODS: A low (30mg/kg/day) and a high (100mg/kg/day) dose of benznidazole were administered to mice infected with Trypanosoma cruzi during the early phases of the infection. The effects of the treatments were assessed at 24 and 90 days postinfection by evaluating the parasitaemia, mortality, histopathological changes and expression of ICAM in the cardiac tissue. The blood levels of thromboxane A2, soluble ICAM and E-selectin were also measured. T. cruzi clearance was assessed by the detection of parasite DNA in the heart tissue of infected mice.
RESULTS: Benznidazole decreased the cardiac damage induced by the parasite, and amastigote nests disappeared at 90 days postinfection. Both doses cleared the parasite from the cardiac tissue at 24 and 90 days postinfection. In addition, benznidazole decreased the thromboxane levels and normalized the plasma sICAM and sE-selectin levels by 90 days postinfection.
CONCLUSIONS: Early administration of benznidazole at a dose as low as 30mg/kg eradicates T. cruzi from cardiac tissue. Additionally, benznidazole prevents cardiac damage and modulates endothelial activation as part of its antichagasic activity.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529066     DOI: 10.1016/j.actatropica.2013.03.006

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  18 in total

1.  Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.

Authors:  Luísa Perin; Rodrigo Moreira da Silva; Kátia da Silva Fonseca; Jamille Mirelle de Oliveira Cardoso; Fernando Augusto Siqueira Mathias; Levi Eduardo Soares Reis; Israel Molina; Rodrigo Correa-Oliveira; Paula Melo de Abreu Vieira; Cláudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Simvastatin Attenuates Endothelial Activation through 15-Epi-Lipoxin A4 Production in Murine Chronic Chagas Cardiomyopathy.

Authors:  Fabiola González-Herrera; Allysson Cramer; Pollyana Pimentel; Christian Castillo; Ana Liempi; Ulrike Kemmerling; Fabiana S Machado; Juan D Maya
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 3.  A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging.

Authors:  Michael D Lewis; Amanda Fortes Francisco; Martin C Taylor; John M Kelly
Journal:  J Biomol Screen       Date:  2014-10-08

4.  Novel Gallate Triphenylphosphonium Derivatives with Potent Antichagasic Activity.

Authors:  Leonel A Cortes; Lorena Castro; Bárbara Pesce; Juan D Maya; Jorge Ferreira; Vicente Castro-Castillo; Eduardo Parra; José A Jara; Rodrigo López-Muñoz
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

5.  Simvastatin and Benznidazole-Mediated Prevention of Trypanosoma cruzi-Induced Endothelial Activation: Role of 15-epi-lipoxin A4 in the Action of Simvastatin.

Authors:  Carolina Campos-Estrada; Ana Liempi; Fabiola González-Herrera; Michel Lapier; Ulrike Kemmerling; Barbara Pesce; Jorge Ferreira; Rodrigo López-Muñoz; Juan D Maya
Journal:  PLoS Negl Trop Dis       Date:  2015-05-15

6.  Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose.

Authors:  Paloma Marina de la Torre-Iglesias; Juan José García-Rodriguez; Guillermo Torrado; Susana Torrado; Santiago Torrado-Santiago; Francisco Bolás-Fernández
Journal:  Drug Des Devel Ther       Date:  2014-09-18       Impact factor: 4.162

7.  Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.

Authors:  Ágata Carolina Cevey; Gerardo Ariel Mirkin; Federico Nicolás Penas; Nora Beatriz Goren
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-12-12       Impact factor: 4.077

8.  In vitro and in vivo trypanocidal activity of H2bdtc-loaded solid lipid nanoparticles.

Authors:  Zumira A Carneiro; Pedro I da S Maia; Renata Sesti-Costa; Carla D Lopes; Tatiana A Pereira; Cristiane M Milanezi; Marcelo A Pereira da Silva; Renata F V Lopez; João S Silva; Victor M Deflon
Journal:  PLoS Negl Trop Dis       Date:  2014-05-08

9.  Acute Chagas outbreaks: molecular and biological features of Trypanosoma cruzi isolates, and clinical aspects of acute cases in Santander, Colombia.

Authors:  Martha Lucía Díaz; Sandra Leal; Julio César Mantilla; Alfredo Molina-Berríos; Rodrigo López-Muñoz; Aldo Solari; Patricia Escobar; Clara Isabel González Rugeles
Journal:  Parasit Vectors       Date:  2015-11-26       Impact factor: 3.876

10.  Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage.

Authors:  Amanda Fortes Francisco; Shiromani Jayawardhana; Michael D Lewis; Karen L White; David M Shackleford; Gong Chen; Jessica Saunders; Maria Osuna-Cabello; Kevin D Read; Susan A Charman; Eric Chatelain; John M Kelly
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.